ERMA Stock Overview
A pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Enorama Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.69 |
| 52 Week High | SEK 8.48 |
| 52 Week Low | SEK 1.71 |
| Beta | 1.45 |
| 1 Month Change | 22.83% |
| 3 Month Change | -12.09% |
| 1 Year Change | -3.58% |
| 3 Year Change | -88.12% |
| 5 Year Change | -90.29% |
| Change since IPO | -65.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERMA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -0.4% | 2.2% | -1.4% |
| 1Y | -3.6% | -0.4% | 2.0% |
Return vs Industry: ERMA underperformed the Swedish Pharmaceuticals industry which returned -0.7% over the past year.
Return vs Market: ERMA underperformed the Swedish Market which returned 2% over the past year.
Price Volatility
| ERMA volatility | |
|---|---|
| ERMA Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ERMA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ERMA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 5 | Daniel Schroder | www.enorama.se |
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.
Enorama Pharma AB (publ) Fundamentals Summary
| ERMA fundamental statistics | |
|---|---|
| Market cap | SEK 162.67m |
| Earnings (TTM) | -SEK 43.81m |
| Revenue (TTM) | SEK 15.77m |
10.3x
P/S Ratio-3.7x
P/E RatioIs ERMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERMA income statement (TTM) | |
|---|---|
| Revenue | SEK 15.77m |
| Cost of Revenue | SEK 12.07m |
| Gross Profit | SEK 3.70m |
| Other Expenses | SEK 47.51m |
| Earnings | -SEK 43.81m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 23.48% |
| Net Profit Margin | -277.82% |
| Debt/Equity Ratio | 0% |
How did ERMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 09:09 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enorama Pharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.